Harrow Health Inc (HROW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harrow Health Inc (HROW) has a cash flow conversion efficiency ratio of -0.317x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.99 Million) by net assets ($28.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View today's stock price for Harrow Health Inc for real-time trading data and today's change.
Harrow Health Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Harrow Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Harrow Health Inc market capitalisation for the company's overall valuation and market capitalisation.
Harrow Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harrow Health Inc ranked by their cash flow conversion efficiency. Also see Harrow Health Inc asset portfolio for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TriMas Corporation
NASDAQ:TRS
|
-0.013x |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
0.013x |
|
RHI Magnesita NV
VI:RHIM
|
0.134x |
|
Parade Technologies Ltd
TWO:4966
|
0.024x |
|
Chinese Universe Publishing And Media Co Ltd
SHG:600373
|
0.034x |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
-0.134x |
|
Black Box Limited
NSE:BBOX
|
0.059x |
|
Jiangsu Longda Superalloy Co. Ltd. A
SHG:688231
|
N/A |
Annual Cash Flow Conversion Efficiency for Harrow Health Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Harrow Health Inc from 2005 to 2025. Review Harrow Health Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.09 Million | $43.86 Million | 0.842x | +362.83% |
| 2024-12-31 | $69.30 Million | $-22.20 Million | -0.320x | -684.06% |
| 2023-12-31 | $70.00 Million | $3.84 Million | 0.055x | -13.50% |
| 2022-12-31 | $26.89 Million | $1.71 Million | 0.063x | -86.36% |
| 2021-12-31 | $10.93 Million | $5.08 Million | 0.465x | +1233.89% |
| 2020-12-31 | $26.83 Million | $-1.10 Million | -0.041x | -218.34% |
| 2019-12-31 | $27.42 Million | $950.00K | 0.035x | +24.83% |
| 2018-12-31 | $24.75 Million | $687.00K | 0.028x | +100.82% |
| 2017-12-31 | $2.62 Million | $-8.80 Million | -3.366x | -93.07% |
| 2016-12-31 | $6.43 Million | $-11.21 Million | -1.744x | -121.67% |
| 2015-12-31 | $-1.39 Million | $-11.14 Million | 8.045x | +1029.39% |
| 2014-12-31 | $8.15 Million | $-7.06 Million | -0.866x | -194.69% |
| 2013-12-31 | $15.11 Million | $-4.44 Million | -0.294x | -54.49% |
| 2012-12-31 | $10.00 Million | $-1.90 Million | -0.190x | -211.02% |
| 2011-12-31 | $-1.70 Million | $-291.16K | 0.171x | -92.26% |
| 2010-12-31 | $-1.04 Million | $-2.30 Million | 2.214x | +135.78% |
| 2009-12-31 | $577.21K | $-3.57 Million | -6.186x | -1016.35% |
| 2008-12-31 | $4.57 Million | $-2.53 Million | -0.554x | -9.67% |
| 2007-12-31 | $3.49 Million | $-1.76 Million | -0.505x | +82.02% |
| 2006-12-31 | $21.35K | $-60.00K | -2.810x | -145.49% |
| 2005-12-31 | $34.99K | $-40.06K | -1.145x | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more